Roivant Sciences Ltd. (ROIV) Stock Analysis
A live, multi-source view of Roivant Sciences Ltd. (ROIV): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
Sector: Healthcare · Industry: Biotechnology · United Kingdom · 721 employees · roivant.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Roivant Sciences Ltd. (ROIV) had a market capitalization of $25.23B (forward -20.3) and a beta of 1.12; the shares traded in a 52-week range of $12.54 – $37.97 (170.6% over the year).
- Market cap
- $25.23B
- Enterprise value
- $22.19B
- Forward P/E
- -20.3
- Price / book
- 5.97
- EPS (trailing)
- $-0.47
- EPS (forward)
- $-1.72
- Payout ratio
- 0.0%
- 52-week range
- $12.54 – $37.97
- 52-week change
- 170.6%
- Beta
- 1.12
- Average volume
- 6.3M
- Shares outstanding
- 722.3M
- Short % of float
- 5.58%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Roivant Sciences Ltd. (ROIV) last closed at $40.94 (the last completed close before that scan).
Technicals at the scan: RSI 68 (neutral territory), price +11.3% versus its 20-day average, 20-day versus 50-day average spread +3.1%, MACD histogram 0.55.
Sentiment inputs: 96% of recent Finnhub-scored headlines read bullish; StockTwits 88% bullish; analyst consensus score 77/100.
Next scheduled company event: in 59 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ROIV; corporate insiders filed 0 buys and 11 sells (3 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mayukh Sukhatme (0B/7S), Eric Venker (0B/3S), Meghan Fitzgerald (0B/1S). Who is trading what
RapidTradeView pick record
ROIV has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Roivant Sciences Ltd. (ROIV) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ROIV.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.